tion prevalence of 1-2% of hepatitis C infection in Western countries. Some 10 -20% of hepatitis C patients develop cirrhosis, and of these, 1-4% per year will develop HCC. Early detection of small tumors as a result of screening programs in cirrhosis will increase the number of patients with a better prognosis and who may be candidates for transplantation.In this issue of the journal, Dr. Poon and the Hong Kong team (1) report their experience with surgical and nonsurgical management of HCC in the elderly. They deserve congratulations for an interesting study, carried out with rigor, and analyzing the many factors involved in the assessment of the risks of surgery and of chemoembolization in the elderly.They have shown that there is not an increased risk in hepatic resection for HCC in patients aged 70 yr or more, for tumors assessed as operable. When tumors are not resectable, patients in this age group can be treated by percutaneous approaches, such as transarterial chemoembolization or ethanol injection for smaller tumors. Cisplatin was chosen as the chemotherapeutic agent for chemoembolization, which in our own experience, seems to give better tumor necrosis than doxorubicin (2).Dr. Poon's team performed a preselection of elderly patients, with exclusion of those with comorbid risk factors. This may have contributed to the good results. Nonetheless, it is important to know that one can carry out a full screening of elderly patients with HCC to select those who will best benefit from resection, and that age by itself, is not a contraindication to surgery. As all of us know, some patients aged 70 or 75 yr are in better physiological condition than younger ones.A second topic that the article raises concerns critical review of institutional practice. Data were stratified into two periods because of a change in surgical technique. The experience of the surgical team is also a key factor. The self-evaluation process highlighted both surgical technique and postoperative management as important in the reduction of hospital mortality and morbidity in HCC. The approach is one that we all could apply to other procedures and pathologies in our quest for continuous improvement in surgical quality and outcomes. This paper is a contribution to surgical science that may reduce age-related treatment bias in the management of the increasing numbers of elderly patients with HCC that are expected in the near future.Henri Bismuth, M.D., F.A.C.S. (Hon.) Centre